Does High PCT Warrant Longer Therapy? - Report - MDSpire
Advertisement
Does High PCT Warrant Longer Therapy?
In a planned BALANCE analysis, elevated day 7 procalcitonin was associated with higher mortality, but the small subgroup analysis found no evidence that extending antibiotics from 7 to 14 days improved outcomes.
A secondary analysis of the BALANCE trial indicates that elevated procalcitonin (PCT) levels after 7 days of antibiotic therapy may not be a reliable indicator for extending antibiotic therapy. The study found no significant benefit in extending antibiotic therapy based on high PCT levels.
Background
Understanding the role of procalcitonin (PCT) in guiding antibiotic therapy duration is crucial, especially in the context of bloodstream infections. Elevated PCT levels have been associated with increased mortality, yet their utility in determining the length of antibiotic treatment remains unclear.
Data Highlights
PCT Level
90-Day Mortality
≥ 250 pg/mL
22% (13 of 60)
< 250 pg/mL
6% (4 of 65)
Key Findings
High PCT levels (≥ 250 pg/mL) were associated with increased 90-day mortality (22% vs. 6% for lower levels).
No significant differences in ICU mortality or hospital-free days were observed between high and low PCT groups.
Extending antibiotic therapy to 14 days did not improve outcomes in patients with elevated PCT levels.
Host factors may contribute to PCT elevations, limiting its use as a standalone guide for antibiotic duration.
The analysis included only 125 patients, limiting the statistical power of the findings.
Clinical Implications
Clinicians should be cautious in using elevated PCT levels as a sole indicator for extending antibiotic therapy duration.
Conclusion
The analysis indicates that elevated PCT levels may not warrant prolonged antibiotic therapy.
